Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm

In a deal that resembles a spin-out but is termed an arms-length transaction, ZymoGenetics transfers eight preclinical programs to Seattle Life Sciences for future considerations, including an equity stake.